Covid-19 treatment drug 2-Deoxy-D-Glucose (2DG). ''2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country,'' the company said in an exchange filing. "Laurus Labs has already applied with the Central Drugs Standard Control Organisation (CDSCO) for emergency use authorization (EUA) for 2DG," it added.
Shares of Laurus Labs Ltd were trading 1.5% higher at ₹677.15 per share on the BSE on Friday. On June 28, pharma major Dr Reddy's announced the commercial launch of 2DG at a maximum retail price of ₹990 per sachet.
DRL will supply to major government as well as private hospitals across India. In the initial weeks, the Company will make the drug available in hospitals